Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Landgren

Showing results (391-400 of 520) with videos related to

Pageof 52
Sort By:
American Journal of Hematology|June 16, 2011
High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, AfricaFrancis Buadi, Ann W Hsing, Jerry A Katzmann, et al.
Blood|March 7, 2009
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantationOla Landgren, Ethel S Gilbert, J Douglas Rizzo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2018
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingSarah A Holstein, J Christine Ye, Alan Howard, et al.
Cancer Immunology Research|May 8, 2025
Identification of the distinct immune microenvironment features associated with progression following high dose melphalan and autologous stem cell transplant in multiple myelomaParvathi Sudha, Travis S Johnson, Habib Hamidi, et al.
Nature Communications|May 7, 2024
The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humansFrancesco Maura, David G Coffey, Caleb K Stein, et al.
The Lancet. Oncology|December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Nature Communications|August 28, 2021
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myelomaKylee H Maclachlan, Even H Rustad, Andriy Derkach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
Functional Impact of Genomic Complexity on the Transcriptome of Multiple MyelomaBachisio Ziccheddu, Matteo C Da Vià, Marta Lionetti, et al.
Oncotarget|April 22, 2017
The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myelomaCaleb K Stein, Charlotte Pawlyn, Shweta Chavan, et al.
Leukemia & Lymphoma|September 30, 2014
Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation methodElisabet E Manasanch, Dalia A Salem, Constance M Yuan, et al.
Pageof 52

Showing results (391-400 of 520) with videos related to

Sort By:
Pageof 52
American Journal of Hematology|June 16, 2011
High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, AfricaFrancis Buadi, Ann W Hsing, Jerry A Katzmann, et al.
Blood|March 7, 2009
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantationOla Landgren, Ethel S Gilbert, J Douglas Rizzo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2018
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingSarah A Holstein, J Christine Ye, Alan Howard, et al.
Cancer Immunology Research|May 8, 2025
Identification of the distinct immune microenvironment features associated with progression following high dose melphalan and autologous stem cell transplant in multiple myelomaParvathi Sudha, Travis S Johnson, Habib Hamidi, et al.
Nature Communications|May 7, 2024
The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humansFrancesco Maura, David G Coffey, Caleb K Stein, et al.
The Lancet. Oncology|December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Nature Communications|August 28, 2021
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myelomaKylee H Maclachlan, Even H Rustad, Andriy Derkach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
Functional Impact of Genomic Complexity on the Transcriptome of Multiple MyelomaBachisio Ziccheddu, Matteo C Da Vià, Marta Lionetti, et al.
Oncotarget|April 22, 2017
The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myelomaCaleb K Stein, Charlotte Pawlyn, Shweta Chavan, et al.
Leukemia & Lymphoma|September 30, 2014
Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation methodElisabet E Manasanch, Dalia A Salem, Constance M Yuan, et al.
Pageof 52